新型口服头孢菌素BMY-28100的体外活性比较

Comparative in vitro activity of the new oral cephalosporin BMY-28100.

作者信息

Aldridge K E, Schiro D D, Sanders C V

出版信息

Eur J Clin Microbiol. 1987 Apr;6(2):170-2. doi: 10.1007/BF02018202.

DOI:10.1007/BF02018202

Abstract

Using a broth microdilution method, the in vitro activity of BMY-28100 against 365 clinical strains of commonly isolated bacteria was determined. BMY-28100 showed good activity against streptococci, methicillin-susceptible staphylococci, Salmonella spp., Shigella spp., and beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Against susceptible strains of these organisms, BMY-28100 showed activity comparable to that of penicillin G, ampicillin, co-trimoxazole, erythromycin, cefaclor, doxycycline and amoxicillin/potassium clavulanate. BMY-28100 had moderate activity against Arizona hinshawii and poor activity against Campylobacter jejuni and Yersinia enterocolitica.

摘要

采用肉汤微量稀释法，测定了BMY - 28100对365株常见分离临床菌株的体外活性。BMY - 28100对链球菌、甲氧西林敏感葡萄球菌、沙门氏菌属、志贺氏菌属以及产β - 内酰胺酶的卡他布兰汉菌和流感嗜血杆菌显示出良好活性。对于这些微生物的敏感菌株，BMY - 28100显示出与青霉素G、氨苄西林、复方新诺明、红霉素、头孢克洛、强力霉素和阿莫西林/克拉维酸钾相当的活性。BMY - 28100对欣肖亚利桑那菌活性中等，对空肠弯曲菌和小肠结肠炎耶尔森氏菌活性较差。